Literature DB >> 15078180

The selective packaging and annealing of primer tRNALys3 in HIV-1.

Lawrence Kleiman1, Rabih Halwani, Hassan Javanbakht.   

Abstract

In HIV-1, tRNA(Lys3) serves as the primer for reverse transcriptase, and during viral assembly, the tRNA(Lys) isoacceptors, tRNA(Lys1,2) and tRNA(Lys3), are selectively packaged into the virion. In this review, we shall first discuss the evidence for the formation of a tRNA(Lys) packaging complex, whose components include Gag, GagPol, genomic RNA, lysyl-tRNA synthetase (LysRS), and tRNA(Lys). Evidence suggests that the formation of this complex involves a Gag/GagPol/viral genomic RNA complex interacting with a tRNA(Lys)/ LysRS complex, with Gag interacting with both GagPol and LysRS, and GagPol interacting with the tRNA(Lys). The interaction of Gag with LysRS is quite specific, does not require the presence of tRNA(Lys), and LysRS is believed to be the target that allows the specific packaging of tRNA(Lys) into the virion. The parameters influencing these interactions, and the molecular sites of interaction, will be discussed. The selective packaging of tRNA(Lys3) into HIV-1 facilitates annealing of tRNA(Lys) to the 5' region of viral RNA genome. This region contains a series of stem loops, and there exists several regions in both the viral RNA and the tRNA(Lys) that are believed to be important for tRNA(Lys) annealing. The annealing is facilitated by viral proteins such as unprocessed Gag, nucleocapsid, and reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078180     DOI: 10.2174/1570162043484988

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  23 in total

Review 1.  Nucleic acid chaperone activity of retroviral Gag proteins.

Authors:  Alan Rein
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  Coordinate roles of Gag and RNA helicase A in promoting the annealing of formula to HIV-1 RNA.

Authors:  Li Xing; Chen Liang; Lawrence Kleiman
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

3.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Yiliang Yang; Robert J Gorelick; Lawrence Kleiman
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 5.  Aminoacyl-tRNA synthetase complexes: molecular multitasking revealed.

Authors:  Corinne D Hausmann; Michael Ibba
Journal:  FEMS Microbiol Rev       Date:  2008-06-03       Impact factor: 16.408

Review 6.  Diverse interactions of retroviral Gag proteins with RNAs.

Authors:  Alan Rein; Siddhartha A K Datta; Christopher P Jones; Karin Musier-Forsyth
Journal:  Trends Biochem Sci       Date:  2011-05-06       Impact factor: 13.807

7.  Defective replication in human immunodeficiency virus type 1 when non-primers are used for reverse transcription.

Authors:  Min Wei; Shan Cen; Meijuan Niu; Fei Guo; Lawrence Kleiman
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Dual role for motif 1 residues of human lysyl-tRNA synthetase in dimerization and packaging into HIV-1.

Authors:  Varun Dewan; Min Wei; Lawrence Kleiman; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

9.  Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1.

Authors:  Fei Guo; Jenan Saadatmand; Meijuan Niu; Lawrence Kleiman
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  HIV-1 modulates the tRNA pool to improve translation efficiency.

Authors:  Anna van Weringh; Manon Ragonnet-Cronin; Erinija Pranckeviciene; Mariana Pavon-Eternod; Lawrence Kleiman; Xuhua Xia
Journal:  Mol Biol Evol       Date:  2011-01-07       Impact factor: 16.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.